Lilly Reports Solid Second-Quarter 2009 Results, Raises EP...(igation claims involving Zyprexa. (b...),Health

Date:7/22/2009

igation claims involving Zyprexa. (b) The second-quarter and year-to-date 2008 financial statements have been adjusted to reflect the acquisition of ImClone as if it was completed by Lilly effective January 1, 2008. ( c ) The 2008 second quarter and year-to-date amounts are adjusted to eliminate a charge of $88.9 million, or $0.05 per share for asset impairments, restructuring and other special charges primarily related to the termination of the AIR(R) Insulin program; a charge of $35.0 million, or $0.02 per share for the in-licensing of a research and development product and technology from TransPharma Medical Ltd; and a charge of $57.1 million, or $0.04 per share for asset impairments included in cost of sales. The year-to-date amounts are also adjusted to eliminate a charge of $145.7 million, or $0.09 per share for asset impairments, restructuring and other special charges primarily related to the termination of the AIR Insulin program; a charge of $87.0 million, or $0.05 per share for acquired in-process research and development associated with the BioMS in-licensing arrangement; and a discrete income tax benefit of $210.3 million, or $0.19 per share as a result of the resolution of a substantial portion of the IRS audit of its federal income tax returns for the years 2001 through 2004.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

'/>"/>

SOURCE Eli Lilly and Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related medicine news :

1. Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)
2. Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo
3. Lilly Sets Date and Conference Call for Second-Quarter 2009 Financial Results Announcement
4. Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
5. Lilly Declares Third-Quarter Dividend
6. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
7. Eli Lilly and Company Announces New Drug Discovery Initiative
8. NAACP & Nine Class Reps File Motion for Class Certification Against Eli Lilly in Pervasive Discrimination Case
9. ICON Selected to Manage Lilly Clinical Trial Site Set Up and Monitoring in Europe
10. Bart Peterson to Join Lilly Leadership Team
11. Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration